Sagent Pharmaceuticals has announced the launch of adenosine injection, an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia. Sagent will offer this latex-free, preservative-free adenosine product in 6mg per 2ml single-dose glass vials for intravenous use.
Jeffrey Yordon, founder, chairman and chief executive officer of Sagent, said: This launch expands upon the full line of prefilled adenosine syringes we introduced in 2007, providing caregivers an array of adenosine delivery options in cardiac care settings. Our 2ml adenosine vial is the second product introduced from our collaboration with Strides Arcolab.
Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 25 injectable products for the US market.